Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer

  • Kelly L. Bolton
  • Georgia Chenevix-Trench
  • Cindy Goh
  • Siegal Sadetzki
  • Susan J. Ramus
  • Beth Y. Karlan
  • Diether Lambrechts
  • Evelyn Despierre
  • Daniel Barrowdale
  • Lesley McGuffog
  • Sue Healey
  • Douglas F. Easton
  • Olga Sinilnikova
  • Javier Benitez
  • Maria J. Garcia
  • Susan Neuhausen
  • Mitchell H. Gail
  • Patricia Hartge
  • Susan Peock
  • Debra Frost
  • Gareth Evans
  • Rosalind Eeles
  • Andrew K. Godwin
  • Mary B. Daly
  • Ava Kwong
  • Edmond S. K. Ma
  • Conxi Lazaro
  • Ignacio Blanco
  • Marco Montagna
  • Emma D'Andrea
  • Maria Ornella Nicoletto
  • Sharon E. Johnatty
  • Susanne Krueger
  • Allan Jensen
  • Estrid Hogdall
  • Ellen L. Goode
  • Brooke L. Fridley
  • Jennifer T. Loud
  • Mark H. Greene
  • Phuong L. Mai
  • Angela Chetrit
  • Flora Lubin
  • Galit Hirsh-Yechezkel
  • Gord Glendon
  • Irene L. Andrulis
  • Amanda E. Toland
  • Leigha Senter
  • Martin E. Gore
  • Charlie Gourley
  • Caroline O. Michie
  • Honglin Song
  • Jonathan Tyrer
  • Alice S. Whittemore
  • Valerie McGuire
  • Weiva Sieh
  • Ulf Kristoffersson
  • Håkan Olsson
  • Åke Borg
  • Douglas A. Levine
  • Linda Steele
  • Mary S. Beattie
  • Salina Chan
  • Robert L. Nussbaum
  • Kirsten B. Moysich
  • Jenny Gross
  • Ilana Cass
  • Christine Walsh
  • Andrew J. Li
  • Ronald Leuchter
  • Ora Gordon
  • Montserrat Garcia-Closas
  • Simon A. Gayther
  • Stephen J. Chanock
  • Antonis C. Antoniou
  • Paul D. P. Pharoah
Publishing year: 2012
Language: English
Pages: 382-390
Publication/Series: JAMA: the journal of the American Medical Association
Volume: 307
Issue: 4
Document type: Journal article
Publisher: American Medical Association

Abstract english

Context Approximately 10% of women with invasive epithelial ovarian cancer (EOC) carry deleterious germline mutations in BRCA1 or BRCA2. A recent article suggested that BRCA2-related EOC was associated with an improved prognosis, but the effect of BRCA1 remains unclear. Objective To characterize the survival of BRCA carriers with EOC compared with noncarriers and to determine whether BRCA1 and BRCA2 carriers show similar survival patterns. Design, Setting, and Participants A pooled analysis of 26 observational studies on the survival of women with ovarian cancer, which included data from 1213 EOC cases with pathogenic germline mutations in BRCA1 (n=909) or BRCA2 (n=304) and from 2666 noncarriers recruited and followed up at variable times between 1987 and 2010 (the median year of diagnosis was 1998). Main Outcome Measure Five-year overall mortality. Results The 5-year overall survival was 36% (95% CI, 34%-38%) for noncarriers, 44% (95% CI, 40%-48%) for BRCA1 carriers, and 52% (95% CI, 46%-58%) for BRCA2 carriers. After adjusting for study and year of diagnosis, BRCA1 and BRCA2 mutation carriers showed a more favorable survival than noncarriers (for BRCA1: hazard ratio [HR], 0.78; 95% CI, 0.68-0.89; P<.001; and for BRCA2: HR, 0.61; 95% CI, 0.50-0.76; P<.001). These survival differences remained after additional adjustment for stage, grade, histology, and age at diagnosis (for BRCA1: HR, 0.73; 95% CI, 0.64-0.84; P<.001; and for BRCA2: HR, 0.49; 95% CI, 0.39-0.61; P<.001). The BRCA1 HR estimate was significantly different from the HR estimated in the adjusted model (P for heterogeneity=.003). Conclusion Among patients with invasive EOC, having a germline mutation in BRCA1 or BRCA2 was associated with improved 5-year overall survival. BRCA2 carriers had the best prognosis. JAMA. 2012;307(4):382-390


  • Cancer and Oncology
  • Medical Genetics


  • ISSN: 1538-3598
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2


Project manager

Familial Breast Cancer



Oncology and Pathology, MV

MV 404 C21C2